The answer is that it depends on the drug and how effective it is and how much value it brings for the cost you're paying for it, right? Now unfortunately, all we can do in setting price ceilings with respect to these types of drugs that are first to market, first in class, have no competitors, is to look at the prices the company that has the patent for that drug is charging in other countries. Those prices do not reflect, as I mentioned, the true price in the market.
Increasingly, what we're seeing is that, because many countries try to control or at least contain costs in the pharmaceutical realm on the basis of what we call external reference pricing, comparing with other countries, there's been a convergence in the pricing of these new drugs that are coming onto the market. There's very little daylight between countries today, so it's not a very valuable reference point. I think that's why we're trying to look at, if those factors are approved, things like value for money, market size, GDP.
It will be a drug-by-drug assessment, so there's no one single answer. There may be instances where a drug that costs a million dollars a year is really good value. It all depends on the clinical effectiveness of that drug and how it compares to other drugs.